Haploidentical hematopoietic stem cell transplantation: State of art

Bone Marrow Transplantation

Volumn 50, Issue , 2015, Pages S1-S5

  Reisner, Y ^a   Aversa, F ^b   Martelli, M F ^c  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b UNIVERSITY OF PERUGIA   (Italy)

^c UNIVERSITY OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; MYCOPHENOLATE MOFETIL; TACROLIMUS; HLA ANTIGEN;

ARTICLE; CANCER RECURRENCE; CELL THERAPY; CHIMERA; DISEASE SEVERITY; DONOR; DRUG MEGADOSE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION; HAPLOTYPE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; IMMUNITY; IMMUNOLOGICAL TOLERANCE; INCIDENCE; LEUKEMIA RELAPSE; MYELOABLATIVE CONDITIONING; NONHUMAN; NONMYELOABLATIVE CONDITIONING; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RECURRENCE RISK; SURVIVAL; SYMPOSIUM; T LYMPHOCYTE; ALLOGRAFT; DISEASE FREE SURVIVAL; GRAFT VS HOST DISEASE; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA; MORTALITY; ORGANIZATION; PATHOLOGY; PROCEDURES; RECURRENT DISEASE; SURVIVAL RATE;

ALLOGRAFTS; CONGRESSES AS TOPIC; DISEASE-FREE SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA ANTIGENS; HUMANS; LEUKEMIA; RECURRENCE; SURVIVAL RATE; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING;

EID: 84930428699     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2015.86     Document Type: Article

References (35)

1. Reisner Y, Itzicovitch L, Meshorer A, Sharon N. Hemopoietic stem cell transplantation using mouse bone marrow and spleen cells fractionated by lectins. Proc Natl Acad Sci USA 1978; 75: 2933-2936.
2. Reisner Y, Kapoor N, O'Reilly RJ, Good RA. Allogeneic bone marrow transplantation using stem cells fractionated by lectins: VI, in vitro analysis of human and monkey bone marrow cells fractionated by sheep red blood cells and soybean agglutinin. Lancet 1980; 2: 1320-1324.
3. Reisner Y, Kapoor N, Kirkpatrick D, Pollack MS, Dupont B, Good RA et al. Transplantation for acute leukaemia with HLA-A and B nonidentical parental marrow cells fractionated with soybean agglutinin and sheep red blood cells. Lancet 1981; 2: 327-331.
4. Reisner Y, Kapoor N, Kirkpatrick D, Pollack MS, Cunningham-Rundles S, Dupont B et al. Transplantation for severe combined immunodeficiency with HLA-A, B, D, DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. Blood 1983; 61: 341-348.
5. Buckley RH, Schiff SE, Schiff RI, Markert L, Williams LW, Roberts JL et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med 1999; 340: 508-516.
6. Pai SY, Logan BR, Griffith LM, Buckley RH, Parrott RE, Dvorak CC et al. Transplantation outcomes for severe combined immunodeficiency, 2000-2009. N Engl J Med 2014; 371: 434-446.
7. Reisner Y, Ben-Bassat I, Douer D, Kaploon A, Schwartz E, Ramot B. Demonstration of clonable alloreactive host T cells in a primate model for bone marrow transplantation. Proc Natl Acad Sci USA 1986; 83: 4012-4015.
8. Kernan NA, Bordignon C, Keever CA, Cunningham I, Castro-Malaspina H, Collins NH et al. Graft failures after T cell depleted marrow transplants for leukemia: clinical and in vitro characteristics. Transplant Proc. 1987; 19: 29-32.
9. Lapidot T, Terenzi A, Singer TS, Salomon O, Reisner Y. Enhancement by dimethyl myleran of donor type chimerism in murine recipients of bone marrow allografts. Blood 1989; 73: 2025-2032.
10. Bachar-Lustig E, Rachamim N, Li HW, Lan F, Reisner Y. Megadose of T celldepleted bone marrow overcomes MHC barriers in sublethally irradiated mice. Nat Med 1995; 1: 1268-1273.
11. Bachar-Lustig E, Li HW, Gur H, Krauthgamer R, Marcus H, Reisner Y. Induction of donor-type chimerism and transplantation tolerance across major histocompatibility barriers in sublethally irradiated mice by Sca-1(+)Lin(-) bone marrow progenitor cells: synergism with non-alloreactive (host x donor)F(1) T cells. Blood 1999; 94: 3212-3221.
12. Aversa F, Tabilio A, Terenzi A, Velardi A, Falzetti F, Giannoni C et al. Successful engraftment of T-cell-depleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 1994; 84: 3948-3955.
13. Reisner Y, Martelli MF. Bone marrow transplantation across HLA barriers by increasing the number of transplanted cells. Immunol Today. 1995; 16: 437-440.
14. Aversa F, Tabilio A, Velardi A, Cunningham I, Terenzi A, Falzetti F et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998; 339: 1186-1193.
15. Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S et al. Full haplotypemismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005; 23: 3447-3454.
16. Bethge WA, Faul C, Bornhaüser M, Stuhler G, Beelen DW, Lang P et al. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update. Blood Cells Mol Dis 2008; 40: 9-13.
17. Bertaina A, Merli P, Rutella S, Pagliara D, Bernardo ME, Masetti R et al. HLA-haploidentical stem cell transplantation after removal of + T and B cells in children with nonmalignant disorders. Blood Cells Mol Dis 2014; 124: 822-826.
18. Ciceri F, Labopin M, Aversa F, Rowe JM, Bunjes D, Lewalle P et al. A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood 2008; 112: 3574-3581.
19. Bastien JP, Roy J, Roy DC. Selective T-cell depletion for haplotype-mismatched allogeneic stem cell transplantation. Semin Oncol 2012; 39: 674-682.
20. Perruccio K, Topini F, Tosti A, Carotti A, Burchielli E, Ruggeri L et al. Optimizing a photoallodepletion protocol for adoptive immunotherapy after haploidentical SCT. Bone Marrow Transplant 2012; 47: 1196-1200.
21. Zhou X, Di Stasi A, Tey SK, Krance RA, Martinez C, Leung KS et al. Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene. Blood 2014; 123: 3895-3905.
22. Di Ianni M, Falzetti F, Carotti A, Terenzi A, Castellino F, Bonifacio E et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011; 117: 3921-3928.
23. Martelli MF, Di Ianni M, Ruggeri L, Falzetti F, Carotti A, Terenzi A et al. HLAhaploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse. Blood 2014; 124: 638-644.
24. Brunstein CG, Miller JS, Cao Q, McKenna DH, Hippen KL, Curtsinger J et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood Cells Mol Dis. 2011; 117: 1061-1070.
25. Leen AM, Bollard CM, Mendizabal AM, Shpall EJ, Szabolcs P, Antin JH et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood Cells Mol Dis. 2013; 121: 5113-5123.
26. Waldmann H. Drug minimization in transplantation: an opinion. Curr Opin Organ Transplant 2014; 19: 331-333.
27. Scandling JD, Busque S, Dejbakhsh-Jones S, Benike C, Millan MT, Shizuru JA et al. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N Engl J Med 2008; 358: 362-368.
28. Scandling JD, Busque S, Shizuru JA, Engleman EG, Strober S. Induced immune tolerance for kidney transplantation. Engl J Med 2011; 365: 1359-1360.
29. Kawai T, Sachs DH, Sprangers B, Spitzer TR, Saidman SL, Zorn E et al. Long-term results in recipients of combined HLA-mismatched kidney and bone marrow transplantation without maintenance immunosuppression. Am J Transplant 2014; 14: 1599-1611.
30. Ciurea SO, Champlin RE. Donor selection in T cell-replete haploidentical hematopoietic stem cell transplantation: knowns unknowns, and controversies. Biol Blood Marrow Transplant 2013; 19: 180-184.
31. Schwartz R, Dameshek W. Drug-induced immunological tolerance. Nature 1959; 183: 1682-1683.
32. Berenbaum MC, Brown IN. Dose-response relationships for agents inhibiting the immune response. Immunology 1964; 7: 65-71.
33. Owens AH Jr, Santos GW. The effect of cytotoxic drugs on graft-versus-host disease in mice. Transplantation 1971; 11: 378-382.
34. Brodsky RA, Luznik L, Bolanõs-Meade J, Leffell MS, Jones RJ, Fuchs EJ. Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic diseases. Bone Marrow Transplantation 2008; 42: 523-527.
35. Luznik L, Bolanõs-Meade Javier, Marianna Zahurak B, Chen AR, Smith BD, Brodsky R et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood Cells Mol Dis. 2010; 115: 3224-3230.